Upgrade to SI Premium - Free Trial

Juno Situation Has Little Impact on Kite Pharma's (KITE) Ongoing ZUMA1 Pivotal Trial - Stifel

November 23, 2016 10:33 AM
Stifel analyst Thomas Shrader weighed in on Kite Pharma (NASDAQ: KITE) after rival Juno Therapeutics has again placed the ROCKET ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Trader Talk

Next Articles